Drugs / Olinciguat
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03892499 | May → Jun 2019 | — | Cyclerion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03795519 | Jan → Feb 2019 | — | Cyclerion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02792998 | May → Nov 2016 | — | Cyclerion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02572349 | Oct → Dec 2015 | — | Cyclerion Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03285178 | Dec 2017 → Jul 2020 | sickle cell disease | Cyclerion Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02931565 | Apr 2017 → May 2018 | achalasia | Cyclerion Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-06-07 | Ironwood Pharmaceuticals, Inc. | Regulatory Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease ironwoodpharma.com ↗
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to olinciguat (IW-1701) for the treatment of patients with sickle cell disease. |
| 2016-02-18 | Ironwood Pharmaceuticals, Inc. | Results Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 ironwoodpharma.com ↗
Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator from Ironwood's vascular and fibrotic disease platform. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-07 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease ironwoodpharma.com ↗ |
| 2017-12-21 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease ironwoodpharma.com ↗ |
| 2017-05-01 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017 ironwoodpharma.com ↗ |
| 2016-02-18 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 ironwoodpharma.com ↗ |
| 2015-11-03 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701 ironwoodpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olinciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02931565 ↗ |
| Known as | IW-1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03285178 ↗ |
| Action | Activate | “A Stimulator of Soluble Guanylate Cyclase (sGC)” NCT02572349 ↗ |
| Modality | Small molecule | — CHEMBL4297616 ↗ |
| Route | Oral | “IW-1701 Administered Orally as Single Doses” NCT02572349 ↗ |